James H. Derrington

Array ( [id] => 10776252 [patent_doc_number] => 20160122408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors' [patent_app_type] => utility [patent_app_number] => 14/992334 [patent_app_country] => US [patent_app_date] => 2016-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 9220 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14992334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10776251 [patent_doc_number] => 20160122407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors' [patent_app_type] => utility [patent_app_number] => 14/992173 [patent_app_country] => US [patent_app_date] => 2016-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 9206 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14992173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12117309 [patent_doc_number] => 20180000895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'METHOD FOR THE TREATMENT OF MALIGNANCIES' [patent_app_type] => utility [patent_app_number] => 15/542415 [patent_app_country] => US [patent_app_date] => 2016-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11891 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15542415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11011333 [patent_doc_number] => 20160208285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/982815 [patent_app_country] => US [patent_app_date] => 2015-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 78400 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14982815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13675231 [patent_doc_number] => 20160376349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => Compositions For diagnosis and Therapy of diseases associated with aberrant expression of Futrins (R-Spondins) and/or Wnt [patent_app_type] => utility [patent_app_number] => 14/757390 [patent_app_country] => US [patent_app_date] => 2015-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14056 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14757390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586419 [patent_doc_number] => 20180344758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => Method of Treating Cancer with cGAMP or cGAsMP [patent_app_type] => utility [patent_app_number] => 15/533687 [patent_app_country] => US [patent_app_date] => 2015-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10978419 [patent_doc_number] => 20160175359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS' [patent_app_type] => utility [patent_app_number] => 14/968853 [patent_app_country] => US [patent_app_date] => 2015-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 119151 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14968853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18492414 [patent_doc_number] => 11697825 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-11 [patent_title] => Compositions and methods for the production of scAAV [patent_app_type] => utility [patent_app_number] => 15/535389 [patent_app_country] => US [patent_app_date] => 2015-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 17 [patent_no_of_words] => 47831 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15535389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19871349 [patent_doc_number] => 12264193 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-01 [patent_title] => Method for producing a recombinant allotypespecific rabbit monoclonal antibody [patent_app_type] => utility [patent_app_number] => 15/533983 [patent_app_country] => US [patent_app_date] => 2015-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 8798 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717823 [patent_doc_number] => 20170369866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => COMPOSITIONS AND METHODS FOR EFFICIENT GENE EDITING IN E. COLI USING GUIDE RNA/CAS ENDONUCLEASE SYSTEMS IN COMBINATION WITH CIRCULAR POLYNUCLEOTIDE MODIFICATION TEMPLATES [patent_app_type] => utility [patent_app_number] => 15/533475 [patent_app_country] => US [patent_app_date] => 2015-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053359 [patent_doc_number] => 20160250321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT' [patent_app_type] => utility [patent_app_number] => 14/954363 [patent_app_country] => US [patent_app_date] => 2015-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 37973 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14954363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10797898 [patent_doc_number] => 20160144055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'GENE THERAPY VECTOR FOR TREATMENT OF STEROID GLAUCOMA' [patent_app_type] => utility [patent_app_number] => 14/949031 [patent_app_country] => US [patent_app_date] => 2015-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 34625 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14949031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10705456 [patent_doc_number] => 20160051603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'Simian Subfamily B Adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/931286 [patent_app_country] => US [patent_app_date] => 2015-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22757 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14931286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058987 [patent_doc_number] => 20170335331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'Altering Gene Expression in CART Cells and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/516240 [patent_app_country] => US [patent_app_date] => 2015-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 143 [patent_figures_cnt] => 143 [patent_no_of_words] => 43032 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378343 [patent_doc_number] => 11236341 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => RNA aptamers against transferrin receptor (TFR) [patent_app_type] => utility [patent_app_number] => 15/519074 [patent_app_country] => US [patent_app_date] => 2015-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 17658 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15519074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236889 [patent_doc_number] => 11180761 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => PDGFR RNA aptamers [patent_app_type] => utility [patent_app_number] => 15/519071 [patent_app_country] => US [patent_app_date] => 2015-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 16168 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15519071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678334 [patent_doc_number] => 20160024480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'RECOMBINANT AAV PRODUCTION IN MAMMALIAN CELLS' [patent_app_type] => utility [patent_app_number] => 14/873498 [patent_app_country] => US [patent_app_date] => 2015-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15096 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14873498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12002141 [patent_doc_number] => 20170306296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'METHOD FOR REESTABLISHMENT OF PLURIPOTENT STEM CELLS' [patent_app_type] => utility [patent_app_number] => 15/516107 [patent_app_country] => US [patent_app_date] => 2015-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 13610 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17937047 [patent_doc_number] => 11471479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Polysaccharide and nucleic acid formulations containing viscosity-lowering agents [patent_app_type] => utility [patent_app_number] => 15/516074 [patent_app_country] => US [patent_app_date] => 2015-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 32539 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504669 [patent_doc_number] => 20180303877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => CELL-BASED TARGETED DELIVERY OF PSEUDONOMAS EXOTOXIN [patent_app_type] => utility [patent_app_number] => 15/513385 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513385 [rel_patent_id] =>[rel_patent_doc_number] =>)